The Association of Combined Total Kidney and Liver Volume with Pain and Gastrointestinal Symptoms in Patients with Later Stage Autosomal Dominant Polycystic Kidney Disease
暂无分享,去创建一个
J. Wetzels | R. Zietse | R. Gansevoort | D. Peters | J. Drenth | N. Casteleijn | T. Gevers | E. M. Spithoven | M. Salih | A. L. Messchendorp | H. D. de Fijter | Hedwig M. A. D’Agnolo | D. Soonawala | F. W. Visser | Maartje D.A. van Gastel
[1] Hyo Sang Kim,et al. Clinical Correlates of Mass Effect in Autosomal Dominant Polycystic Kidney Disease , 2015, PloS one.
[2] B. Kasiske,et al. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. , 2015, Kidney international.
[3] R. Monshouwer,et al. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial , 2015, Liver international : official journal of the International Association for the Study of the Liver.
[4] F. Nevens,et al. Evaluating health‐related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume , 2014, Liver international : official journal of the International Association for the Study of the Liver.
[5] R. Gansevoort,et al. A stepwise approach for effective management of chronic pain in autosomal-dominant polycystic kidney disease. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[6] J. D. de Fijter,et al. Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[7] Kaleab Z. Abebe,et al. Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[8] B. Kerr,et al. The transition from acute to chronic pain: understanding how different biological systems interact , 2014, Canadian Journal of Anesthesia/Journal canadien d'anesthésie.
[9] Luca Antiga,et al. Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial , 2013, The Lancet.
[10] Y. Ubara,et al. Quality of life of patients with ADPKD—Toranomon PKD QOL study: cross-sectional study , 2013, BMC Nephrology.
[11] M. V. van Oijen,et al. Gastrointestinal Symptoms are Still Prevalent and Negatively Impact Health-Related Quality of Life: A Large Cross-Sectional Population Based Study in The Netherlands , 2013, PloS one.
[12] R. Fillingim,et al. Sex differences in pain: a brief review of clinical and experimental findings. , 2013, British journal of anaesthesia.
[13] J. Drenth,et al. Diagnosis and management of polycystic liver disease , 2013, Nature Reviews Gastroenterology &Hepatology.
[14] Eiji Higashihara,et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. , 2012, The New England journal of medicine.
[15] C. Kalkman,et al. Determination of moderate-to-severe postoperative pain on the numeric rating scale: a cut-off point analysis applying four different methods. , 2011, British journal of anaesthesia.
[16] J. Grantham,et al. Why kidneys fail in autosomal dominant polycystic kidney disease , 2011, Nature Reviews Nephrology.
[17] M. V. van Oijen,et al. Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases , 2011, Liver international : official journal of the International Association for the Study of the Liver.
[18] James Glockner,et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. , 2010, Journal of the American Society of Nephrology : JASN.
[19] L. Antiga,et al. Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. , 2010, Clinical journal of the American Society of Nephrology : CJASN.
[20] M. V. van Oijen,et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. , 2009, Gastroenterology.
[21] C. Schmid,et al. A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.
[22] C. Jurkovitz,et al. Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysis. , 2009, Clinical journal of the American Society of Nephrology : CJASN.
[23] M. Numans,et al. Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial , 2009, The Lancet.
[24] P K Commean,et al. Volumetric Measurement of Renal Cysts and Parenchyma Using MRI: Phantoms and Patients with Polycystic Kidney Disease , 2000, Journal of computer assisted tomography.
[25] Kaleab Z. Abebe,et al. Liver involvement in early autosomal-dominant polycystic kidney disease. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[26] Bradley J Erickson,et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. , 2015, Journal of the American Society of Nephrology : JASN.
[27] A. Paterson,et al. Unified criteria for ultrasonographic diagnosis of ADPKD. , 2009, Journal of the American Society of Nephrology : JASN.
[28] F. Windmeijer,et al. R-Squared Measures for Count Data Regression Models With Applications to Health-Care Utilization , 1996 .